Interleukin-21 (IL-21): The "Precision Regulator" of Adaptive Immune Responses

Interleukin-21 (IL-21) is a key member of the γc cytokine family (sharing membership with IL-2, IL-4, IL-7, IL-9, and IL-15), primarily produced by follicular helper T cells (Tfh). Unlike IL-2, which mainly promotes naive T cell proliferation, or IL-4, which drives Th2 differentiation, IL-21's core function lies in the sophisticated regulation of germinal center reactions, humoral immunity, and cytotoxic T cell functions. It plays a unique and critical role in antibody class switching, affinity maturation, plasma cell differentiation, and the modulation of autoimmune and antitumor immunity, serving as a bridge molecule connecting T cell help with B cell responses.

IL-21 is mainly produced by activated CD4⁺ T cell subsets, particularly follicular helper T cells, although activated NKT cells and Th17 cells can also secrete it. Its gene is located on human chromosome 4q26-q27, adjacent to the IL-2 gene. IL-21 is a ~15 kDa four-helix bundle glycoprotein.

IL-21 exerts its effects through its specific receptor (IL-21R), and the expression pattern of this receptor determines the range of cell types it can act upon.

High-affinity receptor (αγ heterodimer): Composed of the unique IL-21Rα chain (CD360) and the shared γc chain (CD132). IL-21 first binds to IL-21Rα, which then recruits the γc chain to form a high-affinity signaling complex.

Broad cellular targets: The IL-21Rα chain is expressed on various immune cells, including B cells, CD8⁺ T cells, NK cells, dendritic cells, and certain CD4⁺ T cells (e.g., Tfh). This expression pattern allows IL-21 to broadly regulate key aspects of adaptive immunity. Notably, naive T cells express low levels of IL-21R, with expression upregulated upon activation, reflecting its role in the effector phase.

IL-21's functions are highly context-dependent, exerting diverse effects across different cell types and microenvironments, but its core role is to act as the "arm" of Tfh cells, regulating B cells and cellular immunity.

Driving B cell differentiation and class switching: Within germinal centers, IL-21 produced by Tfh cells directly acts on B cells, serving as a key signal for their proliferation and differentiation into plasmablasts and plasma cells. IL-21 induces activation-induced cytidine deaminase (AID) expression, promoting antibody class switch recombination (CSR), particularly to IgG1 and IgG3 subtypes.

Regulating plasma cell fate: IL-21 promotes the generation of short-lived plasma cells but has a dual role in long-lived plasma cell formation, depending on coexisting signals (e.g., IL-4 promotes, while IFN-γ inhibits), thereby finely controlling the durability of humoral immunity.

Germinal center maintenance: IL-21 is essential for maintaining normal germinal center structure and function. Defective IL-21 signaling leads to weakened germinal center reactions, impaired affinity maturation, and insufficient production of high-affinity antibodies.

Enhancing CD8⁺ T cell effector functions: IL-21 promotes the proliferation of activated CD8⁺ T cells and enhances their cytotoxicity (granzyme B expression) and IFN-γ production. Unlike IL-2, IL-21 does not induce activation-induced cell death (AICD) and promotes the formation and survival of memory CD8⁺ T cell precursors, demonstrating advantages in maintaining T cell functionality in chronic viral infections and tumor models.

Regulating NK cell maturation and activity: IL-21 influences the terminal differentiation and functional maturation of NK cells from bone marrow to peripheral tissues. It activates mature NK cells, enhancing their cytotoxicity.

Tfh cell proliferation and maintenance: IL-21 acts on Tfh cells in an autocrine or paracrine manner, promoting their proliferation and sustaining the expression of characteristic molecules (e.g., Bcl-6, CXCR5, PD-1), forming a positive feedback loop that reinforces germinal center reactions.

Regulating Th17 cell differentiation: In synergy with TGF-β, IL-21 promotes the differentiation of naive T cells into Th17 cells and induces IL-23R expression on naive T cells, thereby participating in inflammatory and autoimmune pathological processes.

IL-21's signal transduction relies on its receptor complex, with downstream pathway activation patterns similar to other γc family cytokines but characterized by strong STAT3 activation.

JAK-STAT pathway (core pathway):

JAK1/JAK3-STAT1/3/5 activation: Upon IL-21 binding to its receptor, JAK1 (associated with IL-21Rα) and JAK3 (associated with γc chain) are activated. The activated JAK kinases phosphorylate the receptor, primarily recruiting and activating STAT3, though STAT1 and STAT5 can also be activated.

Central role of STAT3: STAT3 phosphorylation and activation are crucial for IL-21-mediated B cell differentiation into plasma cells, plasma cell survival, and Th17 cell differentiation. STAT3 target genes include Blimp-1 (master regulator of plasma cell differentiation) and Bcl-6 (key factor for Tfh/B cell germinal center reactions), explaining the complexity of IL-21's functions.

PI3K-Akt-mTOR pathway:

Activated by IL-21, this pathway primarily mediates cell proliferation, survival, and metabolic reprogramming signals, synergizing with the JAK-STAT pathway to support effector cell expansion.

MAPK pathway:

Participates in regulating cell proliferation and differentiation.

Abnormal IL-21 signaling is closely associated with various autoimmune diseases, immunodeficiencies, and tumor development.

Systemic lupus erythematosus (SLE): Patients exhibit elevated IL-21 levels and excessive pathway activation. IL-21 drives the activation of autoreactive B cells, production of pathogenic autoantibodies (e.g., anti-dsDNA antibodies), and Tfh cell expansion, forming a vicious cycle. IL-21- or IL-21R-targeting monoclonal antibodies have become a key research direction for SLE treatment, showing promise in clinical trials.

Rheumatoid arthritis (RA): Elevated IL-21 levels in synovial tissues of RA patients may exacerbate joint inflammation and bone destruction by promoting Th17 cell differentiation and osteoclastogenesis.

Sjögren's syndrome, autoimmune thyroid diseases, etc.: IL-21 also plays a significant role in organ-specific autoimmune diseases, driving local humoral immunity and inflammatory responses.

Primary immunodeficiencies: Mutations in the IL-21R gene can cause a rare combined immunodeficiency characterized by recurrent infections, hypogammaglobulinemia, and germinal center hypoplasia, directly demonstrating IL-21's critical role in human humoral immunity.

Chronic viral infections: In chronic LCMV, HIV, or HCV infections, IL-21 is essential for maintaining functional CD8⁺ T cell responses and controlling viral load. IL-21 deficiency or impaired signaling leads to CD8⁺ T cell exhaustion and failure to clear viruses.

Vaccine adjuvant potential: Due to its role in promoting germinal center reactions and high-affinity antibody production, IL-21 is considered a potential adjuvant for novel vaccines, especially those requiring robust and durable humoral immunity.

Dual roles:

Antitumor effects: IL-21 directly activates CD8⁺ T cell and NK cell antitumor activity and can inhibit regulatory T cell function. Recombinant IL-21 has been tested as a monotherapy in clinical trials for melanoma and renal cell carcinoma, showing some antitumor activity and manageable toxicity.

Potential protumor effects: In certain B cell lymphomas (e.g., Hodgkin's lymphoma), IL-21 in the tumor microenvironment may promote tumor cell growth via JAK-STAT pathway activation. In solid tumors, IL-21 may indirectly support tumor growth by promoting angiogenesis.

Deeper understanding of IL-21's multifunctionality is driving its exploration in multiple therapeutic areas.

Blocking antibodies: Anti-IL-21 or anti-IL-21R antibodies are among the most promising strategies for treating SLE, RA, and other autoimmune diseases, aiming to suppress pathogenic humoral immunity and Tfh cell responses at their source.

Combination strategies: Combining IL-21 with immune checkpoint inhibitors (e.g., anti-PD-1), adoptive cell therapies (CAR-T, TIL), or tumor vaccines aims to enhance T cell infiltration, functionality, and persistence, overcoming tumor immune tolerance. For example, TIL cells cultured with IL-21 in vitro exhibit stronger antitumor activity and memory phenotypes.

Engineered cytokines: Developing IL-21 variants with longer half-lives and enhanced targeting (e.g., IL-21 immunocytokine fusion proteins) to improve therapeutic indices and reduce systemic toxicity.

Incorporating IL-21 into new vaccine platforms (e.g., mRNA vaccines, viral vector vaccines) to enhance germinal center reactions and induce higher levels of high-affinity, durable neutralizing antibodies, which is particularly important for rapidly mutating viruses like influenza, HIV, and SARS-CoV-2.

Using IL-21 or activating IL-21 signaling during CAR-T or TCR-T cell preparation helps generate more stem-like memory T cells, improving the persistence and efficacy of adoptive cell therapies in vivo.

Interleukin-21 is a meticulous "conductor" in the symphony of adaptive immunity. Rather than initiating a full-scale attack, it finely regulates the quality, intensity, and specificity of immune responses. It uniquely connects Tfh cell help signals with B cell antibody production, determining whether high-quality, high-affinity protective antibodies are generated. Simultaneously, it endows CD8⁺ T cells with sustained combat capability without easily inducing exhaustion. From its role as a "disruptor" in autoimmune diseases to its potential as an "empowerer" in chronic infections and cancer therapy, and its prospects as an "optimizer" in vaccine design, IL-21 research reveals the intricate complexity of immune regulation. In the future, by precisely inhibiting its pathogenic pathways or skillfully harnessing its therapeutic potential, IL-21-related strategies may pioneer new chapters in immunotherapy across autoimmune diseases, infections, tumors, and vaccines.